



## **G1 Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 2, 2022**

October 19, 2022

RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: [GTHX](#)), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2022 on Wednesday, November 2, 2022, at 8:30 a.m. ET.

Please note that there is a new process to access the call via telephone. To register and receive a dial in number and unique PIN to access the live conference call, please follow this [link](#) to [register online](#). While not required, it is recommended that you join 10 minutes prior to the start of the event. A live and archived webcast will be available on the [Events & Presentations](#) page of the company's website: [www.g1therapeutics.com](http://www.g1therapeutics.com). The webcast will be archived on the same page for 90 days following the event.

### **About G1 Therapeutics**

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company's first commercial product, COSELA® (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit [www.g1therapeutics.com](http://www.g1therapeutics.com) and follow us on Twitter @G1Therapeutics.

G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and the COSELA logo are trademarks of G1 Therapeutics, Inc.

### **G1 Therapeutics Contacts:**

Will Roberts  
Vice President  
Investor Relations and Corporate Communications  
(919) 907-1944  
[wroberts@g1therapeutics.com](mailto:wroberts@g1therapeutics.com)

Rebecca Levine  
Director, Corporate Communications and Public Relations  
(919) 667-8711  
[rlevine@g1therapeutics.com](mailto:rlevine@g1therapeutics.com)



Source: G1 Therapeutics